Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s share price traded down 7.8% on Wednesday . The company traded as low as $3.90 and last traded at $3.90. 9,134 shares changed hands during trading, a decline of 90% from the average session volume of 90,658 shares. The stock had previously closed at $4.23.
Qualigen Therapeutics Stock Performance
The stock has a 50-day moving average of $5.31 and a 200-day moving average of $8.53.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.
Featured Stories
- Five stocks we like better than Qualigen Therapeutics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Quiet Period Expirations Explained
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- What does consumer price index measure?
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
